Recommendation Infrastructure
Should Be Accountable to Measurable Progress.

Evidentity is not sold as a collection of AI pages, technical files or monitoring screenshots. The commercial purpose of the system is to improve the clinic's position across agreed high-value recommendation markets: the treatment × geography × patient-scenario decisions in which the business has a legitimate clinical and commercial right to compete. That makes accountability possible. Before managed Recommendation Control begins, Evidentity establishes a baseline showing how the clinic is currently interpreted, which competitors repeatedly receive consideration, where the clinic is captured, contested, substituted or absent, how stable those outcomes are across relevant models and where the principal recommendation barriers appear to sit. The same markets are then observed after infrastructure changes and managed interventions. If Evidentity cannot produce clear measurable improvement against that agreed baseline within six months, the account moves into our Progress Guarantee.

The guarantee is deliberately tied to recommendation progress rather than generic activity. Publishing an AI Site is not progress by itself. Adding structured information is not progress by itself. Producing reports, running tests or changing copy is not progress by itself. The question is whether the clinic's actual position in the priority recommendation markets has moved in a commercially meaningful direction. Evidentity therefore accepts responsibility not merely for installing the infrastructure, but for demonstrating that the infrastructure and operating work are producing observable change where the clinic has an addressable opportunity.

A guarantee is meaningful only when the starting position and the object being improved are defined in advance. Evidentity therefore establishes the clinic's priority recommendation markets before the guarantee period is measured. These are not generic prompts such as “best dentist near me.” They are commercially relevant treatment decisions built around the clinic's actual product: full-arch rehabilitation in a defined geography, failed implant revision, severe bone loss, high-anxiety treatment requiring a particular sedation pathway, complex cosmetic rehabilitation, international treatment or another scenario in which the clinic has a credible reason to seek recommendation consideration.

For each priority market, Evidentity records the current state across repeated model × prompt observations, including clinic inclusion, recurring competitor substitution, unresolved interpretation, Model Divergence and Recommendation Stability. The clinic therefore begins with an owner-level baseline that shows what the recommendation environment looks like before the main intervention programme develops. This baseline becomes the reference against which progress is measured throughout the first six months.

The purpose is to prevent the guarantee from depending on subjective impressions. Ownership can see the starting point, Evidentity can see the starting point, and subsequent movement is evaluated against the same commercial territory rather than against a different set of tests selected after the fact.

Measurable improvement can take several forms because not every clinic begins from the same recommendation state. A clinic that is absent from an important market may improve by entering meaningful consideration. A clinic that is already contested may improve through stronger inclusion, fewer recurring substitutions or more consistent representation across models. A clinic that is regularly recommended for the wrong reason may improve when its actual clinician authority and treatment capability become correctly understood. A multi-location group may improve when specialist capability begins resolving to the correct clinic rather than being flattened across the network.

Evidentity therefore measures progress across the underlying recommendation behaviour, including stronger inclusion in priority markets, reduced recurring competitor substitution, fewer unresolved or materially incorrect interpretations, improved consistency across relevant models, stronger scenario-specific recommendation participation and greater stability of the clinic's correct clinical identity over repeated testing. Several of these can move simultaneously, but the guarantee does not require every metric to improve at once. It requires clear evidence that the clinic's position across the agreed priority markets is becoming stronger than the established baseline.

This is also why Evidentity does not reduce the guarantee to a single universal “AI score.” A clinic moving from complete omission to regular contention has made meaningful progress even if it does not become the most frequently selected provider. A clinic already appearing strongly may make progress through improved stability or by expanding into a high-value scenario that its original recommendation identity failed to resolve. The measurement follows the actual commercial problem the programme was designed to address.

Recommendation markets do not move because a clinic uploads information and waits. During the initial operating period, Evidentity builds and maintains the Canonical AI Clinic Profile, establishes Clinical Intelligence, deploys and synchronises the AI Site, configures the AI Demand Map, monitors the priority treatment markets, identifies recurring competitor substitution and investigates the reasons the clinic is being interpreted differently from the business management actually operates. Where an addressable barrier exists, Evidentity changes the relevant layer and re-tests the same market against the baseline.

Several intervention cycles can therefore occur during the guarantee period. An unresolved clinician-treatment relationship can be strengthened and re-tested. A weak severe-bone-loss position can be investigated against the competitors repeatedly receiving the role. Location ambiguity inside a group can be corrected. Commercial information influencing high-value treatment comparison can be clarified. A new clinic capability can be incorporated into the governed identity and tested against the recommendation markets it should affect. If the first diagnosis does not move the market sufficiently, Evidentity continues investigating rather than treating publication as completion.

The six-month period gives the operating system enough time to establish whether the clinic's recommendation position is responding to the infrastructure and management work, while keeping Evidentity commercially accountable for producing an observable result rather than maintaining activity indefinitely.

At the end of the first six months of managed AI Recommendation Control, Evidentity compares the current state of the agreed priority recommendation markets with the original baseline. Where clear measurable improvement has occurred, the programme continues under the normal operating model, with strong positions moving increasingly toward protection and weaker markets remaining under active management.

If the agreed markets show no clear measurable improvement, responsibility escalates automatically. A Senior Strategic Operator assumes direct responsibility for the account and the additional operating period is provided without monthly AI Recommendation Control fees. The purpose of the escalation is not to repeat the same activity for longer. It creates a second, senior review of the clinic's recommendation architecture, competitor conditions, evidence, source environment, market selection and intervention history to determine why an addressable position has failed to move.

The commercial principle is straightforward: if Evidentity has asked the clinic to invest in an ongoing managed system and the agreed recommendation markets have not demonstrated progress within the initial operating window, the clinic should not continue paying ordinary monthly fees while Evidentity attempts to solve the problem.

The Senior Strategic Operator reviews the complete recommendation environment around the stalled markets. That includes whether the original market remains legitimately addressable, whether the clinic's clinical product has changed, whether an important competitor advantage was underestimated, whether the Canonical Profile contains unresolved relationships, whether the first-party projection is sufficiently authoritative, whether source drift is suppressing the current clinic identity, whether one model is behaving materially differently from the rest and whether the underlying barrier sits outside the layer originally targeted.

This matters because a recommendation position can remain weak for very different reasons. The clinic may be represented incompletely. A newly prominent competitor may have materially changed the market. A clinician relationship may not be supported strongly enough. A broader treatment claim may need to be replaced by a more precise scenario position. The clinic may possess the capability but lack enough public evidence for the recommendation environment to resolve it confidently. In some cases, the deeper analysis may establish that the competitor has a genuine product advantage that materially changes what is realistically recoverable.

The strategic intervention therefore treats the guarantee period as an escalation of analytical responsibility. Evidentity remains responsible for finding the strongest addressable path to progress rather than protecting the original diagnosis.

Once the Progress Guarantee is triggered, Evidentity continues operating the affected recommendation programme for a further 90 days without charging the clinic its normal monthly AI Recommendation Control fee. During that period, the Senior Strategic Operator directs the intervention programme, affected recommendation markets are re-tested and ownership continues receiving the same market intelligence required to understand whether the position is beginning to move.

The additional period matters because the objective is still improvement, not merely financial compensation. If a deeper diagnosis produces the missing change, the clinic leaves the guarantee period with stronger recommendation infrastructure and a more accurate understanding of what drives its position. Evidentity carries the cost of that additional work because the original six-month programme did not produce the agreed level of measurable progress.

This creates a meaningful alignment of incentives. Evidentity benefits when the clinic's recommendation position improves within the normal managed period. If it does not, the additional specialist time and operating cost move to Evidentity rather than remaining with the clinic.

If the agreed priority recommendation markets still show no measurable progress after the additional 90-day Senior Strategic Operator period, Evidentity refunds the monthly AI Recommendation Control fees paid during the guaranteed period. The refund applies to the recurring management layer because that is the layer whose commercial purpose is continuous recommendation improvement, intervention, re-testing and protection.

The implementation work remains the clinic's installed infrastructure. The Canonical AI Clinic Profile, governed treatment and clinician architecture, AI Site and other completed implementation assets are not undone because the recommendation market proved more resistant than expected. The guarantee instead places financial accountability on the ongoing operating function that was responsible for developing the clinic's position after installation.

This distinction keeps the guarantee economically coherent. The clinic receives and retains the infrastructure that was built. Evidentity accepts risk on whether the managed recommendation programme subsequently produces measurable movement across the agreed markets.

A credible guarantee has to begin with markets the clinic is genuinely equipped to serve. Evidentity therefore does not create artificial success targets around treatments, geographies or patient scenarios the business has no clinical basis to contest. A clinic that does not provide IV sedation should not be guaranteed stronger recommendation participation in an IV-sedation scenario. A practice without a serious revision pathway should not treat omission from advanced failed-implant cases as a recommendation failure. A local clinic without an international treatment architecture should not be judged against destination-patient markets simply because they carry high treatment values.

Clinical Intelligence and the initial Demand Map establish the clinic's Addressable Recommendation Footprint before these decisions enter the guarantee. This makes the guarantee stronger rather than weaker because the markets selected for improvement correspond to capabilities the organisation actually owns. Evidentity is therefore accountable for improving how legitimate clinical strength reaches recommendation consideration, not for manufacturing provider suitability where it does not exist.

The clinic's footprint can also change during the programme. A new specialist, sedation capability, international pathway or treatment line can create new addressable markets, while a clinician departure or operating change can remove others. The guarantee remains connected to the current business rather than forcing the clinic to compete against an obsolete baseline.

Recommendation Control could produce impressive-looking activity without producing commercially meaningful progress. A clinic could accumulate more AI mentions in low-value generic queries while remaining absent from the complex treatments management actually cares about. It could appear more often while still being associated with the wrong clinician. It could gain visibility in a geography outside the business's practical catchment while continuing to leak high-value local cases. None of those outcomes should be used to satisfy the guarantee.

The baseline therefore prioritises the specific treatment markets, geographies and patient scenarios agreed as strategically important. Improvement must occur against those markets or another mutually relevant market created by a genuine change in clinic capability. This keeps the operating team focused on the commercial objective rather than on producing the easiest metric to move.

For a premium clinic, the relevant progress might therefore be stronger participation in full-arch rehabilitation, improved severe-bone-loss consideration, reduced substitution in failed implant revision, better international recommendation access, stronger routing toward a specialist hub or another high-value position directly connected to the clinic's desired case mix.

The Progress Guarantee is possible because Evidentity does not stop at diagnosis or publication. The system controls the complete operating workflow around the clinic's recommendation infrastructure: the Canonical AI Clinic Profile establishes current truth; Clinical Intelligence structures treatment depth and clinical authority; the AI Site publishes a governed first-party representation; the AI Demand Map establishes the observed market baseline; Recommendation Intelligence identifies recurring substitution and barriers; Evidentity manages the intervention; and the same recommendation territory is tested again after the change.

That creates a measurable loop:

Baseline → Diagnosis → Intervention → Re-Test → Trend → Protection.

A conventional consultancy can recommend actions and leave the clinic responsible for execution. A software dashboard can report that a problem exists without owning the response. Evidentity operates both the technical infrastructure and the specialist management layer, which means the company can accept responsibility for whether the programme is producing visible progress rather than limiting accountability to whether a deliverable was completed.

The guarantee is therefore not an additional marketing promise sitting outside the product. It is a consequence of the product architecture itself.

Recurring software is easy to sell when success is defined as continued access to the software. Evidentity's monthly service is different because the clinic is not paying merely for a dashboard. The $690/month AI Recommendation Control service combines proprietary technology with a dedicated AI Demand Operator responsible for maintaining, diagnosing and developing the clinic's priority recommendation position. If that specialist function cannot show meaningful progress across an agreed addressable market within a reasonable operating period, Evidentity should share the commercial consequence.

The Progress Guarantee creates that alignment directly. During normal operation, the clinic pays for the technology and specialist function because the recommendation position is being actively developed. If progress fails to materialise within six months, Evidentity assumes the additional operating cost. If the subsequent senior intervention still cannot move the market, the recurring fees from the guaranteed period are returned.

This makes the relationship unusually simple for ownership: Evidentity does not continue collecting ordinary management fees indefinitely while explaining that AI is unpredictable. It establishes a baseline, operates the position, measures the result and carries defined financial responsibility when the agreed progress does not occur.

Premium clinics already take significant commercial risks. They invest in specialist clinicians before every diary is full, acquire advanced technology before every corresponding case arrives, build surgical and restorative capacity before the market has necessarily caught up and spend heavily on acquisition without knowing which prospective patients have already chosen another provider upstream. Evidentity exists to reduce uncertainty in one increasingly important part of that environment: how AI-mediated provider decisions are allocating high-value patient consideration.

That is why the guarantee is based on observable recommendation progress rather than promises of leads, accepted cases or treatment revenue. Evidentity can establish the clinic's recommendation baseline, govern the identity and evidence it controls, monitor the priority markets, diagnose recurring substitution, intervene and measure whether the market position moves. The clinic retains responsibility for the quality of its clinical product and for converting patients once they enter the organisation. Evidentity accepts responsibility for operating the recommendation infrastructure around that product and demonstrating that the addressable recommendation position is becoming stronger.

Six months to demonstrate clear measurable improvement. If that progress does not appear, a Senior Strategic Operator takes over and Evidentity continues the work without monthly Control fees for the next 90 days. If the agreed recommendation markets still do not progress, Evidentity refunds the monthly AI Recommendation Control fees paid during the guaranteed period.

That is the Evidentity Progress Guarantee: not a promise that every AI system will choose the clinic, but a commercial commitment that a managed recommendation programme should produce measurable movement — and that Evidentity carries the cost when it does not.